Description: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in
Patients with Metastatic Solid Tumors
Mechanism of Action: monoclonal antibody targeting galectin-9 (a novel immunotherapy target)
Target Patient Population: All solid tumors.
Study Design: Drug is given IV every 2 weeks of a 28 day cycle